Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Market History and New Update with Current Trends to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market History and New Update with Current Trend
 |
| Non-Small Cell Lung Cancer Therapeutics |
Albany, New York, May 05, 2017
"Non-Small
Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 -
Launch of Premium Targeted Therapies and Increasing Prevalence to
Drive the Market"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Non-Small
Cell Lung Cancer (NSCLC) is the most common cancer and cause of
cancer-related mortality globally. There were more than 1.8 million
newly diagnosed lung cancer cases in 2012 globally, accounting for
13% of the total number of cancer cases. Over half of the incident
cases of NSCLC are diagnosed in patients over the age of 65 - a
high-risk age range for lung cancer. As the aged population is
projected to increase, the prevalence of lung cancer is anticipated
to increase, thereby acting as a driver for revenue growth. The poor
prognosis, particularly for patients with advanced disease, has
created a pressing need for improved therapeutic options. The NSCLC
market is undergoing a gradual change from a focus on generic
chemotherapy regimens to a complex treatment landscape based on
different NSCLC subtypes, and the presence of various molecular
aberrations.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=725317
In
the current market, patients with non-squamous histology can be
treated with more efficacious therapies such as Alimta (pemetrexed),
while patients harboring activating mutations in EGFR or ALK can be
prescribed targeted therapies such as Tarceva, Iressa, Xalkori and
Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor
targeted towards Programmed cell Death (PD) 1 - is a recent market
entrant, gaining approval for treating advanced or metastatic
squamous NSCLC patients in Japan in 2015 and in Australia in 2016.
While the NSCLC developmental pipeline must aim to improve the
outlook for all patients, there is currently a lack of options for
patients with squamous cell histology or other detectable molecular
characteristics besides EFGR and ALK mutations. Therapies that target
mutant T790M and KRAS are being developed in the pipeline, with
osimertinib, targeting T790M, gaining approval in Japan in 2016.
** Scope
– The NSCLC
Asia-Pacific market will be valued at $4.9 billion in 2022, growing
from $2.7 billion in 2015 at a CAGR of 8.7%.
- How will immunotherapies such as Keytruda contribute to the growth?
- What effect will patent expirations of currently branded therapies have on market value?
– The NSCLC pipeline
is large and diverse, with an increased presence of mAbs and targeted
therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
– Numerous late-stage
pipeline therapies with a strong clinical record have the potential
to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
– The market forecasts
indicate that Japan will contribute the most to the Asia-Pacific
market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution influence the market?
– Licensing deals are
the most common form of strategic alliance in NSCLC, with total deal
values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?
** Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.
– Table
of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 13
2.4.1 Adenocarcinoma 14
2.4.2 Squamous-Cell Carcinoma 16
2.4.3 Large-Cell Carcinoma 19
2.4.4 Immunotherapy 20
2.5 Diagnosis 20
2.6 Prognosis 23
2.7 Treatment Guidelines and Options 23
2.7.1 Treatment Algorithm 24
2.7.2 First-Line Treatment 25
2.7.3 Maintenance Therapy 26
2.7.4 Second-Line Treatment 27
2.7.5 Third-Line Therapy 28
2.7.6 Adjuvant Therapy 29
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 13
2.4.1 Adenocarcinoma 14
2.4.2 Squamous-Cell Carcinoma 16
2.4.3 Large-Cell Carcinoma 19
2.4.4 Immunotherapy 20
2.5 Diagnosis 20
2.6 Prognosis 23
2.7 Treatment Guidelines and Options 23
2.7.1 Treatment Algorithm 24
2.7.2 First-Line Treatment 25
2.7.3 Maintenance Therapy 26
2.7.4 Second-Line Treatment 27
2.7.5 Third-Line Therapy 28
2.7.6 Adjuvant Therapy 29
3 Marketed Products 30
3.1 Overview 30
3.2 Chemotherapies 30
3.2.1 Alimta (pemetrexed) - Eli Lilly 30
3.2.2 Abraxane (paclitaxel) - Celgene 31
3.3 Tarceva (erlotinib) - Roche 32
3.4 Iressa (gefitinib) - AstraZeneca 33
3.5 Gilotrif (afatinib) - Boehringer Ingelheim 34
3.6 Xalkori (crizotinib) - Pfizer 35
3.7 Avastin (bevacizumab) - Roche 36
3.8 Opdivo (nivolumab) - Bristol-Myers Squibb 37
3.9 Alecensa (alectinib) - Roche 38
3.10 Conclusion 39
3.11 Comparative Efficacy and Safety of Marketed Products 40
3.1 Overview 30
3.2 Chemotherapies 30
3.2.1 Alimta (pemetrexed) - Eli Lilly 30
3.2.2 Abraxane (paclitaxel) - Celgene 31
3.3 Tarceva (erlotinib) - Roche 32
3.4 Iressa (gefitinib) - AstraZeneca 33
3.5 Gilotrif (afatinib) - Boehringer Ingelheim 34
3.6 Xalkori (crizotinib) - Pfizer 35
3.7 Avastin (bevacizumab) - Roche 36
3.8 Opdivo (nivolumab) - Bristol-Myers Squibb 37
3.9 Alecensa (alectinib) - Roche 38
3.10 Conclusion 39
3.11 Comparative Efficacy and Safety of Marketed Products 40
4 Pipeline Analysis 44
4.1 Overview 44
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 45
4.3 Pipeline by Molecular Target 46
4.4 Promising Pipeline Candidates 49
4.4.1 Ipilimumab - Bristol-Myers Squibb 49
4.4.2 Custirsen - OncoGenex 51
4.4.3 Atezolizumab - Roche 52
4.4.4 Necitumumab - Eli Lilly 54
4.4.5 Rociletinib - Clovis 55
4.4.6 Vaxira - Recombio 57
4.4.7 Keytruda - Merck 58
4.4.8 TG4010 - Transgene 60
4.4.9 Veliparib - AbbVie 61
4.4.10 Abemaciclib - Eli Lilly 63
4.4.11 Bavituximab - Peregrine Pharmaceuticals 64
4.4.12 Cyramza (Ramucirumab) - Eli Lilly 65
4.4.13 Zykadia (ceritinib/LDK378) - Novartis 67
4.4.14 Tagrisso (osimertinib/AZD-9291) - AstraZeneca 68
4.4.15 Dacomitinib - Pfizer 70
4.4.16 Selumetinib - AstraZeneca 71
4.5 Comparative Efficacy and Safety of Pipeline Products 72
4.6 Product Competitiveness Framework 73
5 Clinical Trial Analysis 75
5.1 Failure Rate 75
5.1.1 Overall Failure Rate 75
5.1.2 Failure Rate by Phase and Molecule Type 75
5.1.3 Failure Rate by Phase and Molecular Target 76
5.2 Clinical Trial Size 77
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 78
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 78
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 79
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 80
5.3 Clinical Trial Duration 81
5.3.1 Trial Duration by Molecule Type and Stage of Development 82
5.3.2 Trial Duration by Molecular Target and Stage of Development 82
5.4 Summary of Clinical Trial Metrics 83
4.1 Overview 44
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 45
4.3 Pipeline by Molecular Target 46
4.4 Promising Pipeline Candidates 49
4.4.1 Ipilimumab - Bristol-Myers Squibb 49
4.4.2 Custirsen - OncoGenex 51
4.4.3 Atezolizumab - Roche 52
4.4.4 Necitumumab - Eli Lilly 54
4.4.5 Rociletinib - Clovis 55
4.4.6 Vaxira - Recombio 57
4.4.7 Keytruda - Merck 58
4.4.8 TG4010 - Transgene 60
4.4.9 Veliparib - AbbVie 61
4.4.10 Abemaciclib - Eli Lilly 63
4.4.11 Bavituximab - Peregrine Pharmaceuticals 64
4.4.12 Cyramza (Ramucirumab) - Eli Lilly 65
4.4.13 Zykadia (ceritinib/LDK378) - Novartis 67
4.4.14 Tagrisso (osimertinib/AZD-9291) - AstraZeneca 68
4.4.15 Dacomitinib - Pfizer 70
4.4.16 Selumetinib - AstraZeneca 71
4.5 Comparative Efficacy and Safety of Pipeline Products 72
4.6 Product Competitiveness Framework 73
5 Clinical Trial Analysis 75
5.1 Failure Rate 75
5.1.1 Overall Failure Rate 75
5.1.2 Failure Rate by Phase and Molecule Type 75
5.1.3 Failure Rate by Phase and Molecular Target 76
5.2 Clinical Trial Size 77
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 78
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 78
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 79
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 80
5.3 Clinical Trial Duration 81
5.3.1 Trial Duration by Molecule Type and Stage of Development 82
5.3.2 Trial Duration by Molecular Target and Stage of Development 82
5.4 Summary of Clinical Trial Metrics 83
6 Multi-scenario Forecast 85
6.1 Overview 85
6.2 Asia-Pacific Market 85
6.3 India 87
6.3.1 Treatment Usage Patterns 87
6.3.2 Annual Cost of Therapy 88
6.3.3 Market Size 89
6.4 China 90
6.4.1 Treatment Usage Patterns 90
6.4.2 Annual Cost of Therapy 91
6.4.3 Market Size 92
6.5 Australia 93
6.5.1 Treatment Usage Patterns 93
6.5.2 Annual Cost of Therapy 93
6.5.3 Market Size 94
6.6 South Korea 95
6.6.1 Treatment Usage Patterns 95
6.6.2 Annual Cost of Therapy 96
6.6.3 Market Size 97
6.7 Japan 98
6.7.1 Treatment Usage Patterns 98
6.7.2 Annual Cost of Therapy 99
6.7.3 Market Size 99
6.1 Overview 85
6.2 Asia-Pacific Market 85
6.3 India 87
6.3.1 Treatment Usage Patterns 87
6.3.2 Annual Cost of Therapy 88
6.3.3 Market Size 89
6.4 China 90
6.4.1 Treatment Usage Patterns 90
6.4.2 Annual Cost of Therapy 91
6.4.3 Market Size 92
6.5 Australia 93
6.5.1 Treatment Usage Patterns 93
6.5.2 Annual Cost of Therapy 93
6.5.3 Market Size 94
6.6 South Korea 95
6.6.1 Treatment Usage Patterns 95
6.6.2 Annual Cost of Therapy 96
6.6.3 Market Size 97
6.7 Japan 98
6.7.1 Treatment Usage Patterns 98
6.7.2 Annual Cost of Therapy 99
6.7.3 Market Size 99
7 Market Dynamics (Drivers and Barriers)
101
7.1 Drivers 101
7.1.1 Increasing pollution and passive smoking to drive the incidence 101
7.1.2 Increasing Elderly Population and Incidence of NSCLC 101
7.1.3 The Availability of Novel First- and Second-Line Therapy Options in Pipeline 101
7.1.4 Increase in Mutation Testing to Drive Market Growth 101
7.1.5 Diversified Healthcare Reform to Boost Market Growth 102
7.1 Drivers 101
7.1.1 Increasing pollution and passive smoking to drive the incidence 101
7.1.2 Increasing Elderly Population and Incidence of NSCLC 101
7.1.3 The Availability of Novel First- and Second-Line Therapy Options in Pipeline 101
7.1.4 Increase in Mutation Testing to Drive Market Growth 101
7.1.5 Diversified Healthcare Reform to Boost Market Growth 102
Comments
Post a Comment